Iom Bioworks key facts
as of Oct 2026- Operator of a microbiome-based therapeutic platform intended to improve health by targeting and modulating specific gut bacteria.
- Iom Bioworks is valued at approximately $3.3M as of Oct 2026 (last reported valuation).
- It has raised $460K; the latest was Seed Round ($460K) in Mar 2025.
- Notable investors include Inflection Point Ventures (India), FirstPort Capital, Centre for Cellular And Molecular Platforms.
- Status: Privately Held (backing).
Iom Bioworks's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·Watch Iom Bioworks: the Monday email on marks, rounds and moves
Iom Bioworks funding rounds
No funding rounds for Iom Bioworks are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Iom Bioworks valuation
Iom Bioworks's last reported valuation was $3.3 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Iom Bioworks investors
3 investors are on record for Iom Bioworks, including Inflection Point Ventures (India), FirstPort Capital and Centre for Cellular And Molecular Platforms.
About Iom Bioworks
Operator of a microbiome-based therapeutic platform intended to improve health by targeting and modulating specific gut bacteria. The company offers integrated metagenomic modeling, in silico simulations, systems biology, and microbial process engineering, enabling researchers and healthcare providers to develop personalized interventions based on individual microbiome profiles.
- Sector
- Healthcare
- HQ
- Bangalore, India
- Founded
- 2022
- Employees
- 22
- Website
- iombio.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.